Cite
HARVARD Citation
Pawlyn, C. et al. (2022). Lenalidomide and risk of second primary malignancy—is disease context key?. Lancet. 9 (12), pp. e868-e869. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pawlyn, C. et al. (2022). Lenalidomide and risk of second primary malignancy—is disease context key?. Lancet. 9 (12), pp. e868-e869. [Online].